At present, personalized anti-BC treatment to a large extent depends on tumor morphology, size, lymph-node metastasis, and the expression of such markers as the estrogen receptor (ER), the progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the cellular marker of proliferation Ki-67. Here, MKI67 is linked to neoplasm.